Learn about our rebrand Learn More
Washington, DC (January 27, 2025) – The Melanoma Research Foundation (MRF), the largest independent organization devoted to melanoma, is excited to announce the official ...
The treatment of melanoma with checkpoint inhibitor (CPI) therapy has produced rapid and substantial gains in survival, and as a result, the indications for its use have st...
Uveal melanoma (UM) is a type of aggressive eye cancer that often spreads to the liver and has a poor prognosis. We don’t fully understand how UM spreads, which makes it ...
Description: Immunotherapy has been shown to be effective in treating melanoma, even at an early stage of disease. Patients with Stage II melanoma are now able to receive a...
Traditional cancer therapy involves surgery, radiotherapy, and chemotherapy. These modalities aim to ablate the tumor, yet generally the disease relapses due to the ineffic...
Patients with lymph-node positive melanoma have a high risk of recurrence despite curative surgery. While adjuvant therapy given after surgery improves RFS and OS, ~25% of ...
Melanoma is the most aggressive form of skin cancer. Although progress has been made for advanced melanoma patients with 13 new FDA-approved therapies since 2011, resistanc...
The Hippo pathway in cancer, mediated by YAP1, has been implicated in therapy resistance and aggressive tumor behavior in melanomas treated with targeted therapies. However...
Immune therapies termed “immune checkpoint inhibitors” remove key “brakes” on immune cells. These treatments lead to long-term responses and cures in some patients ...
Description: Immunotherapies, such as CTLA-4 or PD-1 inhibitors, have revolutionized the treatment of metastatic melanoma patients. However, a key challenge to optimize the...
Apr 26, 2025 - Apr 27, 2025
